Figure 4From: Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancerOYS and QOL improvement of Endostar combined with PBDC versus PBDC alone for treating NSCLC. HR, hazard ratio; OR, odds ratio; OYS, one-year survival rate; PBDC, conventional platinum-based doublet chemotherapy; QOL, quality of life.Back to article page